The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells

Clinical and Experimental Rheumatology

Volumn 26, Issue 2, 2008, Pages 295-304

  Kwan Tat, Steve ^a   Pelletier, Jean Peirre ^a   Lajeunesse, Daniel ^a   Fahmi, Hassan ^a   Lavigne, Martin ^b   Martel Pelletier, Johanne ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Osteoarthritis; Osteoblasts; Osteoprotegerin; RANK ligand; Subchondral bone

Indexed keywords

COLECALCIFEROL; INDOMETACIN; INTERLEUKIN 1BETA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BONE MASS; BONE REMODELING; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; FLOW CYTOMETRY; GENE EXPRESSION; GENE FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

AGED; AGED, 80 AND OVER; BONE RESORPTION; CARTILAGE, ARTICULAR; CELL DIFFERENTIATION; DINOPROSTONE; ENERGY METABOLISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMUR; HUMANS; MIDDLE AGED; OSTEOARTHRITIS, KNEE; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 43349095508     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. HILAL G, MARTEL-PELLETIER J, PELLETIER JP, RANGER P, LAJEUNESSE D: Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: Possible role in subchondral bone sclerosis. Arthritis Rheum 1998; 41: 891-9.
2. HILAL G, MARTEL-PELLETIER J, PELLETIER JP, DUVAL N, LAJEUNESSE D: Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. Arthritis Rheum 1999; 42: 2112-22.
3. MANSELL JP, BAILEY AJ: Abnormal cancelous bone collagen metabolism in osteoarthritis. J Clin Invest 1998; 101: 1596-603.
4. BAILEY AJ, SIMS TJ, KNOTT L: Phenotypic expression of osteoblast collagen in osteoarthritic bone: Production of type I homotrimer. Int J Biochem Cell Biol 2002; 34: 176-82.
5. MASSICOTTE F, LAJEUNESSE D, BENDERDOUR M et al.: Can altered production of interleukin 1β, interleukin-6, transforming growth factor-β and prostaglandin E2 by isolated human subchondral osteoblasts identify two subgroups of osteoarthritic patients. Osteoarthritis Cartilage 2002; 10: 491-500.
6. MASSICOTTE F, FERNANDES JC, MARTELPELLETIER J, PELLETIER JP, LAJEUNESSE D: Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone 2006; 38: 333-41.
7. KHOSLATS: Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142: 5050-5.
8. SUDA T, TAKAHASHI N, UDAGAWA N, JIMI E, GILLESPIE MT, MARTIN TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-57.
9. GRAVALLESE EM, GOLDRING SR: Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2143-51.
10. FONSECA JE, CORTEZ-DIAS N, FRANCISCO A et al.: Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: Comparison with other inflammatory arthropathies and correlation with outcome. Clin Exp Rheumatol 2005; 23: 185-92.
11. ALTMAN RD, ASCH E, BLOCH DA et al.: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 1039-49.
12. TARDIF G, HUM D, PELLETIER JP, BOILEAU C, RANGER P, MARTEL-PELLETIER J: Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis Rheum. 2004; 50: 2521-30.
13. KOMAROVA SV, PEREVERZEV A, SHUM JW, SIMS SM, DIXON SJ: Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts. Proc Natl Acad Sci U S A 2005; 102: 2643-8.
14. DEMPSTER DW, HUGHES-BEGOS CE, PLAVETIC-CHEE K et al.: Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem 2005; 95: 139-48.
15. WITTRANT Y, THEOLEYRE S, COUILLAUD S, DUNSTAN C, HEYMANN D, REDINI F: Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-κB ligand and osteoprotegerin biological activities. Exp Cell Res 2004; 293: 292-301.
16. BETTICA P, CLINE G, HART DJ, MEYER J, SPECTOR TD: Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002; 46: 3178-84.
17. ATKINS GJ, KOSTAKIS P, WELLDON KJ, VINCENT C, FINDLAY DM, ZANNETTINO AC: Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. J Cell Physiol 2005; 203: 573-82.
18. ITONAGA I, SABOKBAR A, NEALE SD, ATHANASOU NA: 1,25-Dihydroxyvitamin D(3) and prostaglandin E(2) act directly on circulating human osteoclast precursors. Biochem Biophys Res Commun 1999; 264: 590-5.
19. TAKE I, KOBAYASHI Y, YAMAMOTO Y et al.: Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 2005; 146: 5204-14.
20. RAISZ LG: Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism. J Nutr 1995; 125: 2024S-7S.
21. YASUDA H, SHIMA N, NAKAGAWA N et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-602.
22. FULLER K, WONG B, FOX S, CHOI Y, CHAMBERS TJ: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188: 997-1001.
23. HORWOOD NJ, ELLIOTT J, MARTIN TJ, GILLESPIE MT: Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998; 139: 4743-6.
24. LEE SK, LORENZO JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 1999; 140: 3552-61.
25. HILAL G, MASSICOTTE F, MARTEL-PELLETIER J, FERNANDES JC, PELLETIER JP, LAJEUNESSE D: Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts. J Bone Miner Res 2001; 16: 713-21.
26. SUZUKI J, IKEDA T, KUROYAMA H et al.: Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem Biophys Res Commun 2004; 314: 1021-7.
27. IKEDA T, KASAI M, SUZUKI J et al.: Multimerization of the receptor activator of nuclear factor-kappaB ligand (RANKL) isoforms and regulation of osteoclastogenesis. J Biol Chem 2003; 278: 47217-22.
28. THOMSON BM, MUNDY GR, CHAMBERS TJ: Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987; 138: 775-9.
29. LAVIGNE P, SHI Q, LAJEUNESSE D, DEHNADE F, FERNANDES JC: Metabolic activity of osteoblasts retrieved from osteoarthritic patients after stimulation with mediators involved in periprosthetic loosening. Bone 2004; 34: 478-86.
30. PELLETIER JP, BOILEAU C, BRUNET J et al.: The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 2004; 34: 527-38.
31. AGNELLO KA, TRUMBLE TN, CHAMBERS JN, SEEWALD W, BUDSBERG SC: Effects of zoledronate on markers of bone metabolism and subchondral bone mineral density in dogs with experimentally induced cruciate-deficient osteoarthritis. Am J Vet Res 2005; 66: 1487-95.
32. BRANDT KD, MYERS SL, BURR D, ALBRECHT M: Osteoarthritic changes in canine articular cartilage, subchondral bone, and synovium fifty-four months after transection of the anterior cruciate ligament. Arthritis Rheum 1991; 34: 1560-70.